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Abstract
B-cell development is tightly regulated, including the induction of
B-cell memory and antibody-secreting plasmablasts and plasma
cells. In the last decade, we have expanded our understanding of
effector functions of B cells as well as their roles in human
autoimmune diseases. The current review addresses the role of
certain stages of B-cell development as well as plasma-
blasts/plasma cells in immune regulation under normal and auto-
immune conditions with particular emphasis on systemic lupus
erythematosus. Based on preclinical and clinical data, B cells have
emerged increasingly as both effector cells as well as cells with
immunoregulatory potential.
Introduction
One of the major roles of cells of the B-cell lineage is to
generate antibody-secreting plasmablasts and plasma cells
and also memory B cells with an enhanced capability to
respond to the specific initiating antigen. These effector
functions of the B lineage are well recognized and their roles
in autoimmune diseases are accepted. Knowledge about the
immunoregulatory role of B cells has also been substantially
expanded within the last decade and their functions have
been reconsidered. Historically, B cells have not been
thought to play a major regulatory function in the develop-
ment of autoimmunity and autoimmune diseases, although the
identification of autoantibodies produced by autoreactive
plasma cells and their pathogenic consequences are widely
accepted. It is important to emphasize that B cells
increasingly emerge as part of a tightly regulated immune
activation process with numerous intimate interactions with
other immunocompetent cells that have been identified. Thus,
B cells are considered effector cells as well as cells with
immunoregulatory potential. This review will consider B-cell
involvement as both effector cells and immunoregulatory cells
in the induction and maintenance of systemic autoimmunity
and focus on human systemic lupus erythematosus (SLE) as
a prototypic autoimmune disease.
Under normal resting conditions, B cells follow a tightly
regulated life cycle (Figure 1) with a large number of check
points at indicated stages (antigen-dependent and antigen-
independent selection) to prevent the development of
autoimmunity [1]. In the bone marrow, B cells develop from
stem cells through a series of precursor stages during which
they rearrange their variable immunoglobulin (Ig) genes to
generate a wide range of unique antigen-binding specificities.
Immature CD10+ transitional B cells expressing surface
IgM/IgD emigrate from the bone marrow into the peripheral
blood and then mature into naïve B cells. In the mouse, this
occurs in the spleen, although the site of maturation in
humans is not known [2]. After encountering antigen and T-
cell help in follicles of secondary lymphoid organs, mature
naïve B cells undergo germinal center (GC) reactions leading
to their clonal expansion, somatic hypermutation of Ig gene
rearrangements, and Ig heavy-chain class-switch
recombination. Notably, these complex molecular processes
are unique capacities of B cells and ensure specific higher
avidity binding by the B-cell receptor (BCR) and also the
production of antibodies with altered effector function. During
the GC reaction, naïve antigen-specific B cells mature into
either memory B cells or Ig-secreting plasma cells.
In mice, B1 B cells producing natural antibodies are impor-
tant for the immediate defense against encapsulated bacteria.
Whether they contribute to abnormalities of peripheral B cells
in SLE [3] and primary Sjögren syndrome (pSS) [4] is not
known. The reduced susceptibility of B1 B cells at mucosal
sites after depletion by anti-CD20 therapy [5] suggests
particular survival conditions of these cells in mice. The B1 B-
cell equivalent subset and its role in human autoimmune
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diseases, however, remain to be delineated. Although there is
an increase in CD5+ B cells in both SLE and pSS, these cells
may represent an expended population of pre-naïve conven-
tional B2 cells and not the human equivalent of B1 cells [6]. In
addition, CD5 can be regarded as a B-cell activation marker in
humans and there are no convincing data providing evidence
that it can be used as a lineage marker as accepted in mice.
On the other hand, B2 B cells comprise the adaptive portion
of humoral immune responses. B2 cells participate prefer-
entially in T cell-dependent GC reactions, during which they
can hypermutate their IgV gene rearrangements, switch Ig
classes, and differentiate into memory cells and long-lived
plasma cells. However, B2 cells can also be activated during
T cell-independent responses [7]. B2 precursor cells are
generated in the bone marrow and are subjected to central
tolerance mechanisms. The immature survivors with
functional BCRs leave the bone marrow and migrate to the
periphery and are thought to be exposed to further selection
(peripheral tolerance). Although it has been suggested that
B2 B cells differentiate into either a mature follicular B-cell or
a marginal zone (MZ) B-cell program [8], there are insufficient
data that confirm this in humans. Alternatively, MZ B cells and
B2 B cells can derive from precursor transitional 2 (T2) B
cells that still need additional confirmation. Mouse models
suggest that both B1 and MZ B-cell responses occur
independently of T-cell help and B1 and MZ B cells are
thought to be excluded from undergoing GC reactions. In
conclusion, there appear to be substantial differences
between mice and humans in terms of the specifics of the
differentiation of B-lineage cells. Moreover, the distinct contri-
bution of B1, B2, and MZ B cell-equivalent subsets in human
systemic autoimmunity as well as the role of T cell-indepen-
dent (TI) and T cell-dependent (TD) B-cell activation remain
to be fully delineated. A more precise understanding of these
processes in human autoimmunity would allow us a more
targeted approach to treat specific autoimmune diseases.
Important for the interaction with T cells and the generation of
GC reactions are a series of ligand-receptor interactions,
including those mediated by CD154/CD40 and inducible co-
stimulator ligand/inducible co-stimulator (ICOS-L/ICOS).
Defects in these interactions have been shown to lead to
hyper-IgM syndrome, resulting in impaired plasma cell and
memory B-cell generation, including B lymphopenia and
adult-onset common variable hypogamamglobulinemia, res-
pectively [9,10]. Moreover, the presence of certain cytokines,
such as interleukin (IL)-6, lymphotoxin-β, IL-4, and IL-21, is
required in order to facilitate specific stages of B-cell
differentiation by providing essential co-stimulatory signals.
Because of the complexity of the abnormalities of immune
regulation in systemic autoimmunity, a few key B-cell abnor-
malities will be highlighted since they provide insight into the
nature of perturbations of B-cell function that could contri-
bute to autoimmunity, either in a causative manner or as a
pathway that amplifies disease. In this regard, it is not clear
whether the identified abnormalities of B cells in SLE are
intrinsic or secondary to the disturbed internal milieu
characteristic of SLE.
Figure 1
Schematic B-cell development of B2 B cells emigrating as immature B cells from the bone marrow and differentiating further into naïve/marginal
zone (MZ) B cells in the spleen, which subsequently undergo T cell-dependent differentiation into memory B cells and plasma cells. Secondary
lymphoid tissue refers to spleen, tonsil, lymph node, and Peyer’s patches. CSR, class-switch recombination; GC, germinal center; MALT, mucosal-
associated lymphoid tissue; NF, nuclear factor expression; PC, plasma cells; SC, stem cell; SHM, somatic hypermutation; T1, transitional 1; T2,
transitional 2.1. Defects in proper selection against
autoreactivity during B-cell development
A. Autoantibody production
Currently, the detailed nature of defects in immunologic
check points during B-cell development in SLE is unclear.
However, autoantibodies against double-stranded DNA
(dsDNA) and nucleosomes, serologic hallmarks of lupus, and
other nuclear antigens reflect the breakdown of immune
tolerance. Notably, autoantibodies have been observed in
some patients 6 to 10 years before the onset of the disease
[11-13], indicating that the breakdown of tolerance may
precede and not be secondary to disease activity in SLE. The
processes of recombination and somatic hypermutation for
affinity maturation in the bone marrow and subsequently in
several lymphoid organs, respectively, are followed by strong
selective pressures (‘check points’) under normal conditions
to protect the body from the emergence of B cells with self-
reactivity. In this regard, a number of check points in B-cell
development have been proposed between immature and
mature naïve B cells [14,15].
Examples of abnormalities in selection in patients with SLE
have been reported. The idiotype defined by the 9G4 mono-
clonal antibody that is encoded by VH4-34 heavy-chain gene
rearrangements and frequently used by autoantibodies has
been shown to circumvent negative selection in GCs in
tonsils from SLE patients with subsequent expansion into the
memory B-cell and plasma cell pool [16]. Moreover, the level
of 9G4-expressing B cells as well as 9G4-containing anti-
dsDNA antibodies is related to disease activity in SLE [17].
Compelling evidence of the failure of peripheral tolerance has
also been found in an analysis of somatically mutated VH
gene rearrangements encoding anti-DNA antibodies [18,19],
where back-mutation clearly resulted in loss of binding
activity. These data are consistent with the conclusion that
most but possibly not all anti-DNA antibodies can arise by
somatic mutation from precursors that lack autoantibody
specificity. Therefore, the induction of some autoantibodies
requires activation-induced cytidine deaminase for somatic
hypermutation and Ig switching [20], and their development
occurs  de novo in the periphery fostered by a defect in
peripheral tolerance.
B. Plasmablasts/plasma cells
Although we have acquired a broad knowledge in the use of
autoantibodies in the diagnosis of autoimmunity, less is
known about how autoantibodies are generated in humans.
Clinical data suggest that in patients with active SLE there
are short-lived plasmablasts that are CD27high/HLA-DRhigh-
producing anti-DNA antibodies and their frequency in the
blood correlates with disease activity [17,21,22], whereas
long-lived plasma cells (likely CD27highHLA-DRlow) produce
stable autoantibody titers, such as anti-Sm, -Ro, or -La,
independently of disease activity. Experimental evidence from
mice provided further evidence that plasmablasts and plasma
cells reside in the spleen of lupus-prone mice [23] during
early stages of the disease and that only proliferating
plasmablasts showed susceptibility to cyclophosphamide
treatment. One critical question is whether these major
subsets of Ig-producing cells are generated differently in
autoimmunity [24].
Recently, in SLE patients, a more specific plasmablast subset
that expresses HLA-DR very brightly and that clearly
represents freshly generated plasmablasts was identified
[22,25]. Notably, this cell fraction but not the remaining HLA-
DRlow plasma cells correlated with lupus activity (Systemic
Lupus Erythematosus Disease Activity Index score) and anti-
DNA titers, which indicates that they directly reflect the
activity of SLE. Thus, there is an apparent defect of negative
selection or regulation of newly generated plasmablasts in
SLE, or alternatively, the process is normal but not
appropriately terminated. In this context, proper regulation of
antigen-specific plasmablast generation can be seen after
secondary tetanus vaccination, when these cells appear in
the circulation between days 6 to 8, but their appearance is
downregulated as the immune response wanes [26]. The
data on plasmablasts in murine and human lupus provide
evidence that these cells are susceptible to anti-proliferative
immunosuppressive agents, whereas more differentiated non-
dividing plasma cells show resistance to these drugs [23].
Their distinct contribution to the disease and susceptibility to
therapeutics remain to be assessed.
C. Memory B-cell compartments
There are a number of abnormalities of peripheral B-cell
subsets in human SLE, including an expanded population of
transitional B cells and post-switched CD27+ B cells as well
as the appearance of a distinct population of CD27–/IgD– B
cells with a memory phenotype that is usually not found under
normal conditions (Figure 2). Although their induction and
nature remain poorly understood, it appears that major
perturbations occur in the memory compartment that could
explain disease pathogenesis or resistance to therapy or both
(Figure 3). This is consistent with molecular data that the
peripheral B-cell repertoire in SLE can be shaped by
exaggerated somatic hypermutation, whereas the Ig
repertoire initially generated by V(D)J recombination appears
similar to normal controls [27]. Although the frequency of
memory B cells is increased in the peripheral blood of SLE
patients undergoing immunosuppressive therapy [21], the
specificity of these therapy-resistant memory B cells is
unknown. It is also unclear whether this predominance of
memory B cells reflects a loss of peripheral tolerance or
abnormal selection processes or whether their appearance is
simply the result of an enhanced activation and differentiation
of naïve B cells or their insusceptibility to immunosuppressive
drugs (Figure 3). Independently of these considerations, an
enlarged pool of memory B cells poses a risk for
autoimmunity since these cells have lower activation
thresholds and have passed all check points of the immune
system for negative selection. The enhanced risk for
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memory B cells acquire polyreactivity and autoreactivity
induced by somatic hypermutation [18,19,28].
D. Naïve B cells
Of further interest remains the question of the extent to which
autoimmunity is already contained in the naïve B-cell
repertoire of SLE before an encounter with antigen in the
periphery. This is a difficult question to address in humans.
SLE patients clearly have defects in check points which result
in the appearance of an increased frequency of B cells
capable of polyreactive autoantigen reactivity. Interestingly, a
comprehensive study [15] showed that even inactive SLE
patients fail to remove self-reactive BCRs expressed by naïve
B cells. Consistent with this, earlier studies demonstrated
that self-reactivity or loss of proper selection during early
B-cell development from immature (CD10+ CD27– IgM+
B cells) to mature (CD10– CD27– IgM+ B cells) naïve B cells
is a key feature in SLE [14]. Although these cells appeared to
be influenced neither by antigen nor by T-cell help, the
available data do not allow a conclusion about the detailed
impact of a primary autoimmune predisposition or secondary
influences such as cytokines or co-stimulatory signals. While
it has been debated that polyreactive B cells can represent a
source of autoantibody-secreting cells, formal evidence is
lacking. On one hand, the IgM–/– mouse develops ‘auto-
immunity’ [29]. By contrast, polyreactive IgG antibodies in
SLE may impact on autoimmune manifestations [19].
Although it is tempting to conclude that SLE has defects in
‘check points against autoimmunity’ that explain the
development of pathologic IgG autoantibodies, the possibility
cannot be excluded that these ‘check points’ are active in
SLE to prevent serious autoimmunity but are simply over-
whelmed by chronic polyclonal B-cell activation. Alternatively,
extensive cytokine release and enhanced co-stimulation may
bypass these check points. It is also important to consider
that B cells with a memory phenotype appear among CD27–
B cells previously considered to be exclusively naïve [30,31].
A subset of CD27–/IgD– B cells that express CD95 were
characterized as activated memory B cells with mutated and
Ig-class-switched BCRs. Interestingly, their appearance
correlated with lupus activity,  which is in striking contrast to
the CD27+ memory B-cell population that does not vary
much with disease activity. This CD27– memory subset was
found in patients with SLE but not in patients with infection.
The role of this CD27– memory B-cell subset in the patho-
genesis of SLE remains to be determined.
E. Pre-naïve B cells
Recently, a unique pre-naïve peripheral B-cell population
representing an intermediate stage between transitional and
naïve B cells was identified at enhanced numbers in human
SLE [6]. These cells are CD5+ and express levels of CD38,
CD10, CD9, and the ABCB1 transporter which are inter-
mediate between transitional and naïve B cells. Therefore,
these cells were considered pre-naïve B cells that could be
induced to differentiate into naïve B cells in vitro. These pre-
naïve B cells showed defective responses to BCR stimulation
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Figure 2
Major differences of peripheral B-cell compartments between systemic lupus erythematosus (SLE) patients and normal controls as shown in a
representative dot plot. Please note the increased frequency of Ig-class-switched CD27+ memory B cells and CD27–/IgD– B cells. ND, normal
donors.but intact responses to CD40 ligation, whereas spontaneous
apoptosis and cell death were enhanced compared with
naïve B cells. Of note, B cell-activating factor/B-lymphocyte
stimulator (BAFF/BLyS) was not an essential survival factor of
these pre-naïve cells compared with naïve B cells. Finally,
these cells had the capacity to differentiate into plasma cells
after stimulation and the ability to function as antigen-
presenting cells. The contribution of this population to lupus
pathogenesis remains unknown. It is clear, however, that
disturbances of early stages of B-lymphocyte homeostasis
are also present in SLE and indicate that not only memory
compartments are affected.
2. Aspects of disturbed immunregulation in
systemic lupus erythematosus
A. Regulation of B-cell activation by Fc receptors
The immune system has evolved to defend the organism
against a variety of pathogens and applies threshold mecha-
nisms for regulation. Independently of the co-stimulatory
mechanisms, the coupling of activating and inhibitory
receptors is able to use thresholds for immune cell activation.
IgG immune complexes have long been recognized to have
potent immunoregulatory functions ranging from a strong
enhancement to complete suppression of antibody res-
ponses [32] using selective engagement of specific FcγRs on
discrete cell types, which result in either arrest or progression
of an immune response. Four different classes of Fc
receptors have been defined: FcγRI (CD64), FcγRII (CD32),
FcγRIII (CD16), and FcγRIV [33]. Functionally, there are two
different classes of Fc receptors: the activating and the
inhibitory receptors, which transmit their signals via immuno-
receptor tyrosine-based activation (ITAMs) or immunoreceptor
tyrosine-based inhibitory motifs (ITIMs). Co-expression of
activating and inhibitory molecules on the same cell allows a
balanced immune response, and the biochemical structure of
IgG has substantial influence of the effects on Fc receptors,
resulting in either a pro- or anti-inflammatory response [33].
B. The inhibitory Fcγ γ receptor IIB
The inhibitory Fcγ receptor IIB is part of the family of immune
inhibitory receptors and its loss leads to autoimmunity and
autoimmune disease [34,35]. FcγRIIB is a single-chain recep-
tor that carries an ITIM in its cytoplasmic domain, a hallmark
of this inhibitory protein family, and signals via inositol
phosphatase SHIP (Src homology 2-containing inositol
phosphatase) [36]. With the exception of T cells and natural
killer cells, FcγRIIB is expressed on all cells of the immune
system, including B cells, where it regulates activating signals
delivered by immune complexes. As a consequence of its role
in regulating BCR signals, which ultimately will decide
whether a B cell will undergo proliferation and differentiation
into an antibody-secreting plasma cell, FcγRIIB has been
suggested to play an important role in maintaining peripheral
tolerance [34,35]. The capacity of FcγRIIB to trigger B-cell
apoptosis has been proposed to be another mechanism for
controlling B-cell responses and maintaining self-tolerance.
This hypothesis was supported by the generation of FcγRIIB-
deficient mice that spontaneously develop a lupus-like
disease characterized by the production of autoantibodies
and premature death because of severe glomerulonephritis
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Figure 3
CD27+ B cells with a memory phenotype are less susceptible to cyclophosphamide treatment in patients with systemic lupus erythematosus (SLE)
(n = 20). Severely active SLE patients undergoing monthly intravenous cyclophosphamide bolus therapy were followed for a period of 3 to 6
months. Whereas CD27– B cells and CD27++ plasmablasts/plasma cells showed a decrease, the absolute numbers of CD27+ memory B cells did
not change significantly. n.s., not significant.[37]. Recently, it was suggested that FcγRIIB co-ligation
inhibits BLyS signaling and BLyS-R upregulation following
BCR engagement [38].
C. Polymorphisms in the human Fcγ γRIIB promoter and
autoimmunity
Polymorphisms in the human FcγRIIB promoter linked to
lupus have been identified. One polymorphism leads to
decreased transcription and surface expression of FcγRIIB on
activated B cells of human lupus patients [39]. Another
polymorphism in the transmembrane domain of FcγRIIB is
linked to human lupus in several ethnic populations [33]. It
has been suggested that this allelic variant of the inhibitory
receptor loses its function because of the inability to
associate with lipid rafts [40,41].
Autoreactive B cells can potentially be generated at several
stages during B-cell development. There is accumulating
evidence that FcγRIIB mediates its function during late
antigen-dependent stages of B-cell maturation, thus
representing a distal check point against autoimmunity [33].
Of note, FcγRIIB deficiency did not impact on early events in
the bone marrow, such as receptor editing, nor did it prevent
the development of IgM+ autoreactive B cells. After class-
switching to IgG, however, FcγRIIB was essential to prevent
the expansion of autoreactive B cells and their maturation into
plasma cells [33]. Considering the higher pathogenic
potential of IgG compared with IgM antibody isotypes, this
relatively late stage of FcγRIIB-mediated negative regulation
has a major role in preventing the initiation of severe
autoreactive processes.
Central check points, including receptor editing, deletion, and
anergy of self-reactive BCR species, ensure that the majority
of B cells with an autoreactive BCR are deleted in the bone
marrow [42], which occurs independently of FcγRIIB. In
contrast, autoreactive B cells can be generated de novo by
somatic hypermutation, which is supported by the finding that
many autoantibodies are encoded by somatically mutated VH
gene rearrangements and switched Ig. Here, FcγRIIB might
serve as the final barrier to prevent these B cells with
potentially autoreactive BCR specificities from maturing into
plasma cells.
3. Abnormalities of immune activation in
systemic lupus erythematosus
Co-stimulation results from a complex mix of factors involved
in effective immune activation, which includes antigen
presentation, the provision of soluble and insoluble co-
stimulatory factors as well as the anatomic organization of
secondary lymphoid organs, including the GCs. One
important function of memory B cells is antigen presentation,
which is facilitated by the expression of high-avidity BCR and
also major histocompatibility complex class II molecules.
Under sufficient co-stimulation, memory B cells can effec-
tively present antigen primarily to memory T cells. In mice, MZ
B cells were even shown to provide co-stimulatory activating
signals to naïve T cells [43]. In addition, CD80/CD86
expression on B cells has been shown to be indispensable
for the activation of autoreactive T cells in a murine arthritis
model [44]. The function of B cells as antigen-presenting
cells has also been suggested by instructive data from animal
models [45], in which a lupus-like disease developed when
autoimmune-prone mice were reconstituted with B cells that
lacked the ability to secrete Ig but not when they were
deprived of B cells completely. These studies provided data
on the possible role of antigen presentation by B cells and its
pathogenic relevance.
Antigen presentation by B cells, in particular by memory B
cells, may be important in the amplification and maintenance
of autoimmunity after it has been initiated. Memory B-cell
subsets in SLE [46] provide a sensitive pool of cells that
immediately react to various stimuli, such as Toll-like receptor
(TLR) ligands, IL-21, BAFF, IL-10, BCR activation, or co-
stimulatory signals, resulting in the production of Ig-secreting
cells. Although SLE memory B cells are mainly Ig-class-
switched and show an activated phenotype, it remains to be
determined whether these cells are also effective antigen-
presenting cells. However, while the impact of individual
stimuli is still a matter of debate, the decrease of IgM memory
B cells [47] could represent the result of continuous memory
B-cell activation by elevated BAFF, IL-21, or IL-10 levels [48-51].
Although B cells produce pro-inflammatory cytokines, such
as tumor necrosis factor (TNF) and IL-6, and immuno-
regulatory cytokines, such as IL-10, the immunologic rele-
vance of B cell-derived cytokines is less clear. Furthermore,
convincing evidence for a substantial production of inter-
feron-alpha (IFNα), an important cytokine in SLE [52], by B
cells has not been provided. However, it has been shown that
IFNα is produced by tissue-resident plasmacytoid dendritic
cells, which are reduced in the blood of SLE patients and
may ultimately contribute to B-cell hyperactivity, especially in
lupus nephritis. In this context, a direct effect of IFNα on B
cells is less likely, but IFNα can induce BAFF/BLyS
production of myeloid cells, which can result in enhanced B-
cell survival and potentially activation [53]. BAFF/BLyS or
alternatively APRIL (a proliferation-inducing ligand), which
belong to the TNF ligand family, increase survival of most B-
cell subsets as well as plasma cells. Enhanced BAFF/BLyS
levels could contribute to prolonged survival of autoreactive
cells, which otherwise would be deleted. BAFF/BLyS and
APRIL, therefore, may lead to a vicious cycle of continuous
antibody-mediated inflammation and tissue destruction.
Immune cells of mesenchymal origin produce functional
BAFF/BLyS in response to pro-inflammatory cytokines (TNFα
and IFNγ). Although BAFF transgenic mice [54] develop
autoimmunity with an SLE/Sjögren phenotype, blockade of
this cytokine in human SLE so far has not shown striking
clinical effect but induced changes in Ig and B-cell levels. The
regulatory control of BAFF production by IFNγ and TNFα
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kind of secondary cytokine translating mainly IFN and TNF
effects.
An important immunoregulatory cytokine produced by B cells
is IL-10, which is able to activate dendritic cells to be more
effective antigen-presenting cells and, with the help of T cells,
to enhance the differentiation of memory B cells into plasma
cells in the presence of IL-2 and which may likely be an
important factor of the immunoregulatory function of B cells
[56]. Recently, it was suggested that triggering of TLRs can
induce IL-10 production, which appears to play a role in
protection from chronic inflammatory diseases. Therefore,
immunoregulatory effects of B cells may result from their
IL-10 production in autoimmune diseases. Such a regulatory
function would have important implications for B-cell
depletion therapies, which so far have not been substantiated
by clinical trials. Whether low IL-10 levels after B-cell
depletion ultimately lead to higher IFNγ and TNFα expression,
translating into high BAFF levels, remains open.
With regard to the expression of co-stimulatory ligands
involved in plasma cell and memory B-cell differentiation, it
has been shown that T and B cells from SLE blood spon-
taneously express CD154, which is an indicator that GCs in
this disease abnormally release activated lymphocytes into
the periphery and implies the presence of overactive GCs
[57] or insufficient control mechanisms allowing an egress of
premature memory B cells. Similarly, CD4+ and CD8+ T cells
from lupus patients show enhanced ICOS expression,
whereas memory B cells downregulate ICOS-L, likely as a
result of continuous interaction with T cells [58]. Since these
interactions of the CD28 family are important for memory B-
cell and plasma cell generation but not for the formation of
GCs, they are consistent with the conclusion that there is
overactivated adaptive immunity in SLE and that this repre-
sents an important therapeutic target. All of these distur-
bances of B-cell subsets in adults and children with lupus
with a predominance of memory B cells may also contribute
to the increases of plasmablasts during active lupus [21],
which could be sufficiently blocked by anti-CD154 therapy
[57]. Unfortunately, this therapy [59] had severe side effects
that stopped the trials.
The role of the type I cytokine, IL-21, in the pathogenesis of
SLE has been suggested by a number of recent findings.
First, findings in both humans and mice have indicated an
essential role for this cytokine in co-stimulating B cells to
differentiate into plasma cells [29]. IL-21R–/– mice have a
diminished capacity to produce IgG1 in response to immuni-
zation, whereas IL-21 transgenic mice develop hypergamma-
globulinemia [60]. Overexpression of IL-21 is found in the
BXSByaa and the sanroche murine models of SLE [61].
Finally, blocking of IL-21 activity successfully treats the
manifestations of lupus in the MRL mouse, whereas crossing
the BXSByaa mouse with the IL-21R–/– mouse prevents all
manifestations of SLE [62]. IL-21 is produced by CXCR5+
follicular helper T cells, which require ICOS stimulation for
their generation [61]. These findings link ICOS and IL-21 in a
definable pathway required for B-cell stimulation in secondary
lymphoid organs and suggest that blocking IL-21 may be
effective in human SLE. Formation of ectopic GCs has been
identified in the kidneys of patients with SLE, in the salivary
glands of patients with Sjögren syndrome, in the thymus in
patients with myasthenia gravis, and in the central nervous
system of patients with multiple sclerosis [4,58,63]. Although
these aggregates of CD20+ B cells surrounded by T cells
and follicular dendritic cells have been found in only a fraction
of patients, it is not known whether their formation is related
to disease activity or T cell-dependent or -independent
activation or whether they have the full capacity to select
antigen-reactive cells and delete autoreactive B cells
appropriately as in typical GCs.
Even though ectopic GCs have been linked to local over-
activation of autoimmune B cells and plasma cells, conclusive
evidence that they are required for the development of auto-
immune diseases or are secondary to the deranged internal
environment characteristic of these conditions has not been
provided. Thus, no firm conclusion on the differences in the
nature of classic GC versus ectopic GC in autoimmunity can
be drawn since even classic GCs in tonsils from SLE patients
were found to be defective in selection against 9G4 B cells
as an indicator of anti-dsDNA activity [16].
An area of interest within the last decade has been the role of
T cell-independent activation of B cells. While this can occur
in vitro, ligating one of the receptors for BAFF/BLyS and
APRIL, the transmembrane activator and calcium modulator
and cyclophilin ligand interactor (TACI) [64-68], in only a
subset of memory B cells [69], conclusive evidence concern-
ing the role of this pathway in SLE is lacking.
Another mechanism by which B cells can be activated in the
absence of T cells is via TLR activation. TLRs are also known
as ‘pathogen-associated molecular pattern receptors’ or
‘pattern recognition receptors’ and are expressed by nearly
every cell in the body. TLR-7, TLR-8, and TLR-9 are the most
important of these with respect to B-cell activation. Bacterial
DNA is the natural ligand of TLR-9, and single-stranded RNA
is the ligand of TLR-7 and TLR-8. All three receptor-ligand
interactions apparently lead to activation of B cells by an NF-
κB (nuclear factor-kappa-B)-dependent mechanism [70,71].
So far, the most convincing data available for human SLE
concern TLR-9 and B-cell activation. As a result of TLR-9
stimulation, B cells can differentiate into (auto)antibody-
producing plasma cells or produce pro-inflammatory cyto-
kines [71]. Signaling via TLRs uniquely affects memory B
cells [72]. The available data, however, suggest the possi-
bility that memory B cells in patients with SLE could easily be
activated via TLR-9 without T-cell help and therefore could
account for the expansion in peripheral plasmablasts.
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activated immune system and apparent multiple abnormalities
of B-cell development can be assumed in SLE. This
permanent overactivation (of whatever cause) might over-
whelm all possible check capacities of the immune system.
Consistent with that, early check points before antigen or
T-cell influences have been identified to be defective [14,15],
classic GCs do not select properly [16], and ectopic GCs
with a potential lack of selection are found in SLE that may
permit the emergence of autoreactive cells.
4. Lessons from immune intervention trials
After therapeutic trials of anti-CD4 therapy in RA [73] and
SLE [74] failed to show substantial clinical benefit, questions
about the central role of CD4+ T cells were raised. Recent
success achieved by blocking T-cell co-stimulation with
CTLA4Ig (abatacept) by antigen-presenting cells, including B
cells, and the effects of blocking CD40/CD154 interactions
on autoimmunity [57,59] have again implied a role for the
regulatory interaction of immune cells in systemic auto-
immune diseases. However, in SLE, the use of anti-CD154
(BG9588) led to some safety concerns with thromboembolic
complications [59] in lupus nephritis, although clear immuno-
logic effects were seen. Moreover, blockade of ICOS-L was
shown in mice to reduce lupus nephritis [75].
The success of B cell-depleting therapy in ameliorating
rheumatoid inflammation and joint destruction has docu-
mented a role for B cells in RA but also in other autoimmune
diseases, such as idiopathic thrombocytopenic purpura and
SLE [76]. Interestingly, a reduction of expressed co-stimu-
latory molecules such as CD80, CD86, and CD40L on
T cells after B-cell depletion was observed in SLE [77], a
reduced infiltration of CD68 macrophages was noted in the
RA synovium [78], and an increase of regulatory T cells was
seen in autoimmune thrombocytopenia [79]. It is clear from
these clinical trial results that B cells together with other
immune cells play important roles in autoimmunity. However,
their role in the induction versus maintenance phase of the
disease and the specific contributions of particular B-cell
subsets have not been dissected in detail. Although previous
data in lupus have shown that B-cell hyperactivity and the
resulting autoantibody production are central elements of the
immunopathogenesis of SLE, preliminary data of the use of
rituximab as an anti-CD20 antibody in non-renal (EXPLORER
trial) [80] and renal (LUNAR trial) SLE have reportedly failed
the primary endpoints. Although it remains possible that anti-
B-cell therapy is not sufficient to suppress lupus activity, a
number of other confounding variables of SLE trial design
may have substantially contributed (too short trial duration,
allowance of substantial glucocorticoid usage, heterogeneity
of the patient population, etc). Since a number of additional
early trials in SLE, such as the use of abatacept and
abetimus, have not provided convincing therapeutic effects,
the most likely explanation is that lupus patients are hetero-
geneous with regard to organ manifestations and patho-
physiology and require customized therapeutic strategies.
Patients need to be stratified and characterized in detail prior
to the choosing of a certain therapeutic approach. Parameters
like the ‘interferon signature’, BLyS levels, and serologic and
clinical findings should be considered and validated
regarding their predictive value as biomarkers. In this regard,
frequently detectable autoantibodies against DNA are
produced by short-lived plasma cells versus anti-extractable
nuclear antigens produced by apparently long-lived plasma
cells. Given that both produce pathogenic autoantibodies,
therapies should target both. Future assessments will be
necessary to determine whether B cell-directed therapy can
be effective clinically in SLE but also to test the hypothesis
that specific B-cell abnormalities are essential for the
pathogenesis of this disease. A further explanation of recent
trial failure could be that the British Isles Lupus Assessment
Group (BILAG) scoring system is less sensitive to changes in
the BILAG B, which may preclude a sufficient discrimination
of therapeutic success. Overall, the results of recent lupus
trials challenge the rheumatology community to improve trial
approaches in SLE, a patient population in need of improved
therapies.
A different B cell-directed approach is targeting CD22 on B
cells; CD22 is uniquely expressed on mature B cells but not
on plasma cells or pre-B cells. The humanized anti-CD22
monoclonal antibody epratuzumab causes partial B-cell
reduction in the blood, inhibits B-cell proliferation, and
probably interferes with intracellular signaling. Preliminary
results from an open-label phase IIa study indicate that
epratuzumab is efficacious in SLE [81], with BILAG index
scores improving by more than 50% in 77% of treated
patients at week 6. A central question yet to be answered is
how partial inhibition of B-cell activation may affect the
clinical risk-benefit ratio as compared with total depletion as
mediated by anti-CD20 antibodies. Partial inhibition might
mean that B cells can still be activated by certain pathogens
in this setting while epratuzumab (anti-CD22) inhibits
activation of autoreactive B cells. A preferential reduction of
naïve B cells in the peripheral blood under epratuzumab
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A Decade of Progresstreatment has been seen in clinical study. It has not been
resolved whether this was caused by preferential depletion or
apoptosis of naïve B cells or by enhanced migration of these
cells from the blood into the tissue. In vitro data, however,
suggested that this agent acts also by blocking proliferation
of B cells [46], an effect that has been observed in patients
with SLE but not in normal controls [46].
The current data are consistent with the conclusion that
B-cell abnormalities in SLE can be targeted by cellular
approaches, such as anti-B-cell therapy, but also inter-
ventions on key cytokines, such as IFNα, or blocking co-
stimulation. A critical question will be to identify a common
denominator of B-cell activation as a target that allows
sufficient and safe immune intervention.
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